First Week of XP August 2026 Options Trading

The piece highlights option strategies on XP Inc. (current price $16.15): selling the $12 put (bid $0.55) commits purchase at $12 with an effective cost basis of $11.45, a ~26% discount to spot, and Stock Options Channel estimates a 79% chance it expires worthless (YieldBoost 4.58% or 6.83% annualized). Alternatively, writing the $17 covered call (bid $1.85) against shares yields a 16.72% total return if called at the August 2026 expiration, with a 5% upside strike premium and a 45% probability of expiring worthless (YieldBoost 11.46% or 17.07% annualized). Implied volatilities are ~66% (put) and 63% (call) versus a trailing 12‑month realized volatility of 42%; Stock Options Channel will track contract odds and charts on its site.

Analysis

Market Structure: Elevated implied vol (IV 66% puts, 63% calls vs 42% realized) signals expensive optionality and a seller-friendly environment if liquidity holds. Short-dated premium favors option-writing: $12 Aug‑2026 put yields 4.58% on cash (6.83% ann.), $17 covered call yields 16.72% to Aug‑2026 (17.07% annualized) — attractive if willing to own/limit upside. Exchanges and derivatives desks (e.g., NDAQ) benefit from higher volumes and spreads; retail buying could be hurt if volatility collapses and options sellers capture outsized returns.

Risk Assessment: Tail risks include sharp BRL depreciation (>10% in 30 days), Brazil regulatory action on wealth managers, or a rebound in realized vol that gaps XP below $12; such moves would turn premium harvesting into large mark-to-market loss. Near term (days–weeks) option sellers face gamma risk around earnings or macro prints; medium term (months) exposure to Brazil macro/elections; long term positioning depends on XP fundamentals and FCF growth. Hidden dependencies: low open interest or wide bid-ask spreads can prevent timely rolls, and assignment risk requires cash liquidity equal to strike*shares.

Trade Implications: Primary trade — SELL Aug‑2026 XP $12 put (collect $0.55) sized to 1–2% portfolio with cash reserved at $12 for assignment; plan to buy back if IV drops 20% or spot > $14 within 60 days. If already long XP, SELL Aug‑2026 $17 covered calls to lock 16.7% upside; consider collars (buy $14 put) if downside protection required. For volatility players, implement calendar spreads (sell long‑dated IV, buy nearer‑dated realized vol) rather than naked short strangles given IV>realized by ~50%.

Contrarian Angles: Consensus focuses on yieldboost but underestimates Brazil FX and regulatory gamma — if BRL weakens 10% or XP misses growth metrics, downside to $10-$11 is plausible, making put-selling costly. Conversely, IV is likely overstated vs realized absent macro shock; disciplined premium sellers with assignment liquidity can extract ~5–17% returns annualized — a persistent mispricing if macro remains stable. Historical parallel: emerging-market fintechs see episodic vol spikes; size positions conservatively and predefine roll/assignment rules to avoid concentration risk.

Key Decisions for Investors

• Establish a sell-to-open position in XP (ticker: XP) Aug‑2026 $12 put up to 1–2% portfolio weight, collect ~$0.55; allocate full cash at $12/share for assignment and buy back/roll if IV falls ≥20% or spot > $14 within 60 days.
• If purchasing XP equity, layer covered calls: buy XP at or below $16.15 and sell Aug‑2026 $17 calls (collect ~$1.85) to lock ~16.7% upside; add a $14 protective put (cost‑limit 1.0% portfolio) if max drawdown tolerances are 10–15%.
• Trade volatility: implement a defined‑risk calendar by selling one Aug‑2026 $17 call and buying two nearer‑dated calls to hedge gamma (size 0.5–1% portfolio); exit if realized vol rises to exceed IV by >10 pts or if BRL/USD moves >5% in 7 days.
• Monitor three catalysts over next 90 days and act: Brazil macro (BRL moves ±5%), XP quarterly revenue/ARPU beats or misses, and any regulatory notices on wealth‑management fees — reduce option‑selling exposure by 50% if any occur.
• Avoid naked short strangles; cap total notional from XP option selling to ≤5% of portfolio due to assignment liquidity risk and potential emergent BRL/regulatory tail scenarios.